a direct-to-consumer study investigating the effect of specific cannabinoid products on motivation, energy level, focus, and appetite in healthy adults

Conditions: Motivation

Summary: tetrahydrocannabivarin (thcv) is a rare cannabinoid and is a homologue of thc that differs only in the length of the alkyl side chain (3c vs 5c, respectively). pre-clinical and clinical trials have shown that thcv has medical potential as a neuroprotectant, anti-inflammatory, anti-anxiety, and most notably as a therapeutic to improve glycemic control in type 2 diabetic patients. several thcv products are available in states with recreational cannabis. anecdotal reports from adult cannabis users indicate that thcv provides an energizing, focusing and euphoric high-while still creating a lucid, uplifting experience. additionally, unlike thc-dominant products, thcv was not reported to increase appetite. other anecdotal comments referring to increased ability to focus for long periods of time and being more active were common. given anecdotal evidence, which shows that thcv is activating and improving focus, this provides rationale and justification to conduct a clinical research study to further test and understand whether thcv improves motivation, focus, level of energy, and does not stimulate appetite in healthy adults.

the rationale for this study is to determine the effect of a consumer-grade, state-legal formulation of cannabinoids including tetrahydrocannabivarin (thcv) on motivation, energy level, focus, and appetite. a consumer-driven, decentralized observational clinical research study is therefore well suited to examine the effect of this formulation in healthy individuals. the investigators will examine the outcomes in a broad age-range of adults who have chosen to try these products. the study will incorporate participant reported outcomes and surveys collected after each product use session to engage the participant in their typical day-to-day activities. there is no "physician-patient" relationship as part of this research since the participant as a consumer is making the informed choice to take the products and take part in the observational process with self-reported measures. findings from this study will contribute knowledge toward the design of future cannabis research studies and the improvement of the product formulation. a new study questionnaire was developed as no existing questionnaire would be able to capture all interest areas of this study in a holistic manner. other questionnaires related to focus, attention, concentration, fatigue, work, and motivation were assessed and used to support the study questionnaire development.

Eligibility criteria:
inclusion criteria: 1. healthy adults age \> 21 years old 2. work / study / play in an environment that requires focus 3. able to read and understand english 4. able to read, understand, and provide informed consent 5. able to use a personal smartphone device and download chloe by people science 6. able to complete study assessments over the course of up to 14 days 7. familiar with the use of cannabis and its effects 8. able to tolerate at least 5mg thc 9. willingness to abstain from use of any thc containing products during study product use days 10. willingness to abstain from use of alcohol during study product use days 11. greater los angeles area residents only exclusion criteria: 1. participants who do not have a smartphone and/or internet access 2. any known adverse effects from taking cannabis 3. concomitant therapies: currently taking medication for adhd or psychotropic medications 4. other illnesses or conditions: participants who have the following co-morbidities are excluded: 1. history or currently undergoing product use for substance abuse disorders 2. currently pregnant, planning to become pregnant within the next month, or breastfeeding 3. allergies to formulation ingredients 4. current or prior psychotic disorder 5. immunosuppressive product uses, including organ transplant participants, active immunotherapy for cancer product use 6. any condition that is considered by investigator to be a contraindication to cannabis (e.g. specific drug-use interaction, unstable cardiac arrhythmia)